PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS) announced the pricing of its underwritten public offering of 3,586,500 shares of its common stock ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE